REFERENCES
- Asai T, Liu Y, Bae N, The p53 tumor suppressor protein regulates hematopoietic stem cell fate. J. Cell. Physiol. 2011;226(9):2215–2221.
- Lin K, Adamson J, Johnson GG, Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration. Clin Cancer Res. 2012;18(15):4191–4200.
- Mirzayans R, Andrais B, Scott A, New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol. 2012; doi: 10.1155/2012/170325.
- Pant V, Quintas-Cardama A, Lozano G. The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood. 2012;120(26):5118–5127.
- Ortega FJ, Moreno-Navarrete JM, Mayas D, Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 (p53) expression. Int. J Obes. 2013; [Epub ahead of print] doi: 10.1038/ijo.2013.163
- Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–310.
- Ceccaldi R, Parmar K, Mouly E, Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell. 2012;11(1):36–49.
- Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol. 2007;39(7–8):1476–1482.
- Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329(18):1318–1327.
- Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat. 2003;21(3):277–284.
- Jadersten M, Saft L, Smith A, TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29(15):1971–1979.
- Hof J, Krentz S, van Schewick C, Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011;29(23):3185–3193.
- Holmfeldt L, Wei L, Diaz-Flores E, The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3):242–252.
- Gustafsson B, Axelsson B, Gustafsson B, MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr Hematol Oncol. 2001;18(8):497–508.
- Gustafsson B, Christenson B, Hjalmar V, Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis. Med Pediatr Oncol. 2000;34(2):117–124.
- Felix CA, Hosler MR, Provisor D, The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood. 1996;87(10):4376–4381.
- Saito S, Matsuda K, Taira C, Genetic analysis of TP53 in childhood myelodysplastic syndrome and juvenile myelomonocytic leukemia. Leuk Res. 2011;35(12):1578–1584.
- Silveira CG, Oliveira FM, Valera ET, New recurrent deletions in the PPARgamma and TP53 genes are associated with childhood myelodysplastic syndrome. Leuk Res. 2009;33(1):19–27.
- Miyauchi J, Asada M, Tsunematsu Y, Abnormalities of the p53 gene in juvenile myelomonocytic leukaemia. Br J Haematol. 1999;106(4):980–986.
- Hasle H, Baumann I, Bergstrasser E, The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). 2004;18(12):2008–2014.
- Gohring G, Michalova K, Beverloo HB, Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood. 2010;116(19):3766–3769.
- Niemeyer CM, Arico M, Basso G, Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997;89(10):3534–3543.
- Suttorp M, Eckardt L, Tauer JT, Management of chronic myeloid leukemia in childhood. Curr Hematol Malignancy Rep. 2012;7(2):116–124.
- Iwasaki T, Murakami M, Sugisaki C, Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia. Pathol Int. 2008;58(6):353–360.
- Hazard FK, Zhao S, Schiffman JD, Tissue microarrays from bone marrow aspirates for high-throughput assessment of immunohistologic markers in pediatric acute leukemia. Pediatr Dev Pathol. 2008;11(4):283–290.